Medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak are a crucial component to the united states government?s (USG?s) outbreak response plan. Biomedical advanced…

Active Definitive Contract Awarded Last action

Contract number
75A50123C00037
Awardee
Awarding agency
Obligated
$118,563,679

Award facts

Opportunity
  • 75A50122R000006 Solicitation number
Contract value 8% obligated
  • $237,127,358.00 Current, with exercised options
  • $1,525,625,390.00 Potential, with all options
Completion date 32% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Montgomery Village, MD 20879, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00010 · The purpose of this no-cost modification is to update several articles. $0
Other Administrative Action P00009 $0
Other Administrative Action P00008 · The purpose of this no-cost modification is to article g.11 negotiated indirect cost rate based on documentation from NIH dated march 19, 2025AND article i.1… $0
Exercise an Option P00007 · The purpose of this modification is to exercise and fully fund option 2/CLIN0003 and update article b.3 estimated cost plus fixed fee clins. $16,674,751
Other Administrative Action P00006 · The purpose of this modification is to update articles b.1 brief description of supplies and services, b.5 advance understandings, c.1 statement of work dated… $0
Exercise an Option P00005 · The purpose of this modification is to exercise and fully fund option 1/CLIN0002 and update article b.3 estimated cost plus fixed fee clins. $41,914,902
Other Administrative Action P00004 · The purpose of this modification is to update articles b.5. Advance understandings (h) quality agreement shall be submitted for approval no later than october… $0
Other Administrative Action P00003 · The purpose of this modification is to update article g.4 key personnel. $0
Other Administrative Action P00002 · The purpose of this modification is to update article c - description/specifications/work statement adding additional work requested by the FDA at no additional… $0
Other Administrative Action P00001 · The purpose of this modification is to update article b.5. Advance understandings (h) quality agreement shall be submitted for approval no later than june 28,… $0
Original award $59,974,026
Show all 11

About this award

Written by GovTribe AI ·

The Biomedical Advanced Research and Development Authority (BARDA), operating under the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, awarded a definitive firm fixed price contract to Emergent Product Development Gaithersburg Inc. valued at approximately $1.53 billion. This no-cost modification updates contract articles for the development of medical countermeasures targeting filovirus outbreaks, which are identified as critical components of the U.S. government's outbreak response strategy. The contract extends through July 29, 2033, with work to be performed at the contractor's Gaithersburg, Maryland facility.

Emergent Product Development Gaithersburg Inc., a for-profit pharmaceutical and medical countermeasures manufacturer registered in SAM.gov since 2002, brings substantial experience in federal contracting, having received over $1.3 billion in prime contracts from HHS and Defense agencies since 2019. The company specializes in developing vaccines, therapeutics, and medical countermeasures for public health threats, including previous work on smallpox vaccines and other biological defense initiatives. This filovirus contract represents a significant continuation of BARDA's efforts to maintain a robust portfolio of medical countermeasures for emerging infectious disease threats, with no set-aside designation applied to this award.

Description

As the agency reported it.

Medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak are a crucial component to the united states government?s (USG?s) outbreak response plan. Biomedical advanced research and development authority (barda) is seekin

Quick answers

Who was awarded contract 75A50123C00037?

75A50123C00037 was awarded to Emergent Product Development Gaithersburg Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on July 31, 2023.

How much is contract 75A50123C00037 worth?

The government has obligated $118,563,679 on 75A50123C00037. Its current value, with exercised options, is $237,127,358. Its potential value, with all options, is $1,525,625,390.

Was contract 75A50123C00037 competed?

The extent of competition for 75A50123C00037 was full and open competition. The government received 2 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login